10 results about "PYY Peptide" patented technology

The invention discloses a structural modification and optimization method of a PC-PYY peptide based on molecular dynamics simulation and a product thereof. The method specifically comprises the following steps: respectively constructing a PC-PYY peptide model and a candida albicans model; establishing a simulation box, solvating the model, adding Na < + > and C1 <-> to neutralize the system, and performing energy minimization; simulating a finished product and optimizing a polypeptide amino acid sequence; carrying out molecular dynamics simulation on the modified PC-PYY peptide and the candida albicans model again; comparing and analyzing data results of the initial PC-PYY peptide and the modified PC-PYY peptide; the obtained peptide chain enhances the selective binding capacity to a fungal membrane and improves the antifungal efficacy of the peptide chain.

To provide pharmaceutical compositions for the treatment of metabolic disorders, and to provide methods for treating metabolic disorders.SOLUTION: Pharmaceutical compositions comprising PYY (e.g., PYY (3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Such aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY (3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.SELECTED DRAWING: Figure 1

The invention relates to a cyclic peptide tyrosine-tyrosine conjugate coupled with a glucagon-like peptide 1 (GLP-1) fusion peptide and application of the cyclic peptide tyrosine-tyrosine conjugate. The present invention includes a conjugate comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods of use thereof. The novel conjugates are useful for preventing, treating, or ameliorating diseases and disorders disclosed herein.

Provided herein are compositions and methods for treating and / or preventing pathogenic fungal infection and for maintenance of microbiome commensalism. In particular, provided herein are compositions comprising modified peptide YY (PYY) peptides and therapeutic and / or prophylactic methods of use thereof.

The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder: wherein the peptide is a piscine-derived PYYor fragment or analogue thereof.

Provided are pharmaceutical compositions containing PYY (e.g., PYY(3-36) and its analogs and variants), sataiety peptides, sataiety hormones, metabolic hormones, and methods for treating metabolic disorders with such compositions. These embodiments include methods for enhancing well-being in patients treated with pharmaceutical compositions containing PYY, PYY(3-36), sataiety peptides, sataiety hormones, metabolic hormones, and analogs, receptor antagonists, and variants thereof.

The present invention includes conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The present invention also relates to pharmaceutical compositions and methods of use thereof. The novel conjugates can be used to prevent, treat or ameliorate the diseases and disorders disclosed herein.

Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.

The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYY or fragment or analogue thereof.

The present invention relates to the pharmaceutical field, and specifically, to the following general formula (I): P-K-P-E-ψ-P-E-X 10 -D-X 12 -S-P-E-E-W-Q-R-Y-Y-X 22 -X 23 -L-R-H-Y-L-N-W-L-T-R-Q-R-Y-R1(I) A novel peptide tyrosine-tyrosine (PYY 3~36 ) analog or a salt or solvate thereof is provided, which contains the array structure as described above. The novel peptide YY analog (PYY 3~36 ) provided by the present invention has better pharmacological effects, longer action time, excellent bioavailability and safety.